Clinical trials: Zoledronic acid
Lung Cancer
Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer
Pilot study of Zoledronic acid in combination with first-line chemotherapy in aged patients with lung cancer. The purpose is to assess the effects of Zoledronic acid in combination with first-line chemotherapy in aged patients…
- Trial name
- NCT01737216
- Testing
- Zoledronic acid plus EP/TP, EP/TP
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Tumor Hospital
Leukemia, Lymphoma
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis
- Trial name
- NCT00321932
- Testing
- calcium, cholecalciferol, zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Minnesota
Osteoporosis
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736693
- Testing
- Raloxifene, Zoledronic Acid
- Where
- United States
- Volunteers
- 18,028 people
- Sponsor
- Brigham and Women's Hospital
Prostatic Neoplasms, Bone Density
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Trial name
- NCT00489905
- Testing
- Zolderonic acid (Zometa)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hospital Authority, Hong Kong
Breast Cancer
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer.
- Trial name
- NCT00127205
- Testing
- clodronate disodium, ibandronate sodium, zoledronic acid
- Volunteers
- 6,097 people
- Sponsor
- SWOG Cancer Research Network
Osteoporosis
Denosumab Safety Assessment in Multiple Observational Databases
This is a prospective open-cohort study with annual assessment and reporting of descriptive findings from 5 secondary data sources, US Medicare, Optum Research Database (formerly United HealthCare), Scandinavian national health…
- Trial name
- NCT02520362
- Testing
- denosumab, bisphosphonate
- Volunteers
- 517,991 people
- Sponsor
- Amgen
Breast Neoplasms, Breast Cancer
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid…
- Conditions
- Breast Neoplasms, Breast Cancer, Metastasis
- Trial name
- NCT00051779
- Testing
- CAL
- Where
- 38 sites in United States
- Sponsor
- Chugai Pharma USA
Postmenopausal Osteoporosis
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide.
- Trial name
- DATA-HD (NCT02176382)
- Testing
- denosumab, teriparatide, Zoledronic acid
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hormone-Refractory Prostate Cancer
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
- Trial name
- NCT00151073
- Testing
- Zoledronic acid, Estramustine, Docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Kidney Disease, Osteoporosis
Pharmacokinetics of Zoledronic Acid in Patients on Dialysis
Osteoporosis is a frequent complication of chronic kidney disease (CKD) on dialysis, with an estimated prevalence of approximately 40%. It is associated with increased fracture risk, reduced quality of life, and higher mortality.
- Conditions
- Chronic Kidney Disease, Osteoporosis, Dialysis
- Trial name
- ZADIAL (NCT07741136)
- Testing
- Zoledronic Acid Injection, 5.0 mg, single dose, Zoledronic Acid Injection, 2.5 mg, single dose
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil
Prostate Cancer, Bone Metastases
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients
This study was undertaken to evaluate bone response in metastatic prostate cancer patients treated with Enzalutamide with or without Zoledronic Acid in combination with luteinizing hormone-releasing hormone (LHRH) analogue with…
- Trial name
- BonEnza (NCT03336983)
- Testing
- Zoledronic Acid, Enzalutamide
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Breast Cancer With Metastatic Bone Disease
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
The aim of this prospective, randomized, open-label, multicentric clinical study is to assess the effícacy and tolerability of zoledronic acid 4 mg IV infused over 15 minutes every 4 weeks for a total of 6 infusions, in…
- Trial name
- NCT00172029
- Testing
- Zoledronic acid
- Where
- 7 sites in Turkey (Türkiye)
- Volunteers
- 116 people
- Sponsor
- Novartis
Metastatic Cancer, Prostate Cancer
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.
- Trial name
- NCT00079001
- Testing
- zoledronic acid, androgen deprivation therapy, GnRH agonist
- Where
- 241 sites in United States, Canada
- Volunteers
- 645 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Osteoporosis, Osteopenia, Osteoporosis
Intervention Study of Drugs in Patients Osteopenia and Osteoporosis
This is a 12 months, randomized, multicenter, open-label, parallel-group study in postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China to evaluate the efficacy and safety of different…
- Trial name
- NCT04719572
- Testing
- Basic treatment group, Basic treatment+ anti-osteoporosis drug group, Basic treatment + non-drug treatment group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
The purpose of this research study is to define the time a molecule in the participants bones called NTX begins to rise after receiving treatment with bisphosphonates.
- Trial name
- NCT00577642
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Chronic Periodontitis
Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis
The investigators evaluated the effect of initial periodontal treatment on clinical findings and receptor activator of Nuclear Factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in gingival crevicular fluid (GCF) of patients…
- Trial name
- NCT02808988
- Testing
- periodontal phase 1 therapy, gingival crevicular fluid collection, zoledronic acid
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Adenocarcinoma
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.
- Trial name
- NCT00892242
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Osteoporosis
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial.
- Trial name
- NCT00145327
- Testing
- Zoledronic Acid
- Where
- 31 sites in United States, Germany
- Volunteers
- 2,456 people
- Sponsor
- Novartis
Metastatic Cancer, Prostate Cancer
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554918
- Testing
- docetaxel, prednisolone, zoledronic acid
- Where
- 16 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University Hospital Birmingham
Advanced Bladder Cancer
A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
We plan to enroll 20-29 patients with advanced bladder cancer to undergo T-cell therapy. Each treatment cycle consists of three T-cell infusions, with two cycles planned per patient.
- Trial name
- γδ-T-BLADDER (NCT07204496)
- Testing
- Ex Vivo Expanded γδ T Cell Infusion
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital